HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

McKesson investment in FoxMeyer would total $400 mil.; agreement awaits FTC approval.

This article was originally published in The Rose Sheet

Executive Summary

McKESSON $80 MIL. FOXMEYER OFFER EARMARKED FOR TRADE DEBT, CREDITOR CLAIMS related to FoxMeyer's Chapter 11 bankruptcy filing, the wholesalers said Oct. 4. FoxMeyer and McKesson have reached a definitive agreement for McKesson to acquire the assets of FoxMeyer's distribution business. The two firms anticipate the sale will be completed in November. Until then, FoxMeyer will continue to operate its drug and H&BA distribution business. FoxMeyer filed for federal bankruptcy protection on Aug. 27.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS003330

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel